Intrinsic value of Stemline Therapeutics - STML

Previous Close

$11.37

  Intrinsic Value

$0.39

stock screener

  Rating & Target

str. sell

-97%

Previous close

$11.37

 
Intrinsic value

$0.39

 
Up/down potential

-97%

 
Rating

str. sell

We calculate the intrinsic value of STML stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  1
  2
  3
  5
  7
  9
  13
  16
  21
  27
  33
  41
  49
  58
  69
  80
  92
  105
  119
  133
  149
  166
  183
  201
  220
  239
  260
  281
  303
  326
Variable operating expenses, $m
  55
  84
  126
  183
  258
  355
  477
  626
  805
  1,017
  1,263
  1,544
  1,861
  2,215
  2,604
  3,029
  3,489
  3,984
  4,512
  5,073
  5,666
  6,290
  6,945
  7,631
  8,347
  9,094
  9,872
  10,682
  11,523
  12,398
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  55
  84
  126
  183
  258
  355
  477
  626
  805
  1,017
  1,263
  1,544
  1,861
  2,215
  2,604
  3,029
  3,489
  3,984
  4,512
  5,073
  5,666
  6,290
  6,945
  7,631
  8,347
  9,094
  9,872
  10,682
  11,523
  12,398
Operating income, $m
  -53
  -82
  -123
  -178
  -252
  -346
  -464
  -609
  -784
  -990
  -1,230
  -1,504
  -1,812
  -2,156
  -2,536
  -2,950
  -3,398
  -3,879
  -4,393
  -4,939
  -5,517
  -6,124
  -6,762
  -7,430
  -8,128
  -8,855
  -9,612
  -10,400
  -11,220
  -12,071
EBITDA, $m
  -53
  -82
  -123
  -178
  -251
  -346
  -464
  -609
  -784
  -990
  -1,229
  -1,503
  -1,812
  -2,156
  -2,535
  -2,948
  -3,396
  -3,878
  -4,392
  -4,937
  -5,514
  -6,122
  -6,760
  -7,427
  -8,124
  -8,851
  -9,609
  -10,396
  -11,215
  -12,067
Interest expense (income), $m
  0
  0
  0
  1
  3
  4
  6
  9
  13
  17
  22
  28
  35
  43
  53
  63
  74
  86
  100
  114
  129
  145
  162
  180
  199
  219
  240
  261
  284
  307
  331
Earnings before tax, $m
  -53
  -83
  -124
  -181
  -256
  -352
  -473
  -622
  -801
  -1,013
  -1,258
  -1,539
  -1,856
  -2,209
  -2,598
  -3,024
  -3,484
  -3,979
  -4,507
  -5,068
  -5,662
  -6,287
  -6,943
  -7,629
  -8,347
  -9,095
  -9,873
  -10,684
  -11,527
  -12,403
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -53
  -83
  -124
  -181
  -256
  -352
  -473
  -622
  -801
  -1,013
  -1,258
  -1,539
  -1,856
  -2,209
  -2,598
  -3,024
  -3,484
  -3,979
  -4,507
  -5,068
  -5,662
  -6,287
  -6,943
  -7,629
  -8,347
  -9,095
  -9,873
  -10,684
  -11,527
  -12,403

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  51
  79
  119
  172
  243
  334
  448
  588
  757
  956
  1,187
  1,451
  1,749
  2,082
  2,448
  2,847
  3,280
  3,744
  4,241
  4,768
  5,325
  5,912
  6,527
  7,172
  7,845
  8,547
  9,278
  10,039
  10,830
  11,652
Adjusted assets (=assets-cash), $m
  51
  79
  119
  172
  243
  334
  448
  588
  757
  956
  1,187
  1,451
  1,749
  2,082
  2,448
  2,847
  3,280
  3,744
  4,241
  4,768
  5,325
  5,912
  6,527
  7,172
  7,845
  8,547
  9,278
  10,039
  10,830
  11,652
Revenue / Adjusted assets
  0.020
  0.025
  0.025
  0.029
  0.029
  0.027
  0.029
  0.027
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
  0.028
Average production assets, $m
  0
  0
  0
  0
  1
  1
  1
  1
  2
  2
  3
  3
  4
  5
  5
  6
  7
  8
  9
  11
  12
  13
  15
  16
  18
  19
  21
  22
  24
  26
Working capital, $m
  -28
  -43
  -64
  -93
  -132
  -181
  -243
  -319
  -411
  -519
  -644
  -787
  -949
  -1,129
  -1,327
  -1,544
  -1,779
  -2,031
  -2,300
  -2,586
  -2,888
  -3,206
  -3,540
  -3,890
  -4,255
  -4,636
  -5,032
  -5,445
  -5,874
  -6,320
Total debt, $m
  9
  25
  47
  78
  118
  170
  235
  314
  410
  523
  654
  804
  974
  1,162
  1,370
  1,597
  1,843
  2,107
  2,389
  2,688
  3,005
  3,338
  3,688
  4,054
  4,436
  4,835
  5,250
  5,682
  6,131
  6,598
Total liabilities, $m
  29
  45
  67
  98
  138
  190
  254
  334
  430
  543
  674
  824
  994
  1,182
  1,390
  1,617
  1,863
  2,127
  2,409
  2,708
  3,025
  3,358
  3,708
  4,074
  4,456
  4,855
  5,270
  5,702
  6,151
  6,618
Total equity, $m
  22
  34
  51
  74
  105
  144
  194
  254
  327
  413
  513
  627
  756
  899
  1,057
  1,230
  1,417
  1,618
  1,832
  2,060
  2,300
  2,554
  2,820
  3,098
  3,389
  3,692
  4,008
  4,337
  4,679
  5,034
Total liabilities and equity, $m
  51
  79
  118
  172
  243
  334
  448
  588
  757
  956
  1,187
  1,451
  1,750
  2,081
  2,447
  2,847
  3,280
  3,745
  4,241
  4,768
  5,325
  5,912
  6,528
  7,172
  7,845
  8,547
  9,278
  10,039
  10,830
  11,652
Debt-to-equity ratio
  0.420
  0.730
  0.930
  1.050
  1.120
  1.180
  1.210
  1.240
  1.250
  1.270
  1.280
  1.280
  1.290
  1.290
  1.300
  1.300
  1.300
  1.300
  1.300
  1.310
  1.310
  1.310
  1.310
  1.310
  1.310
  1.310
  1.310
  1.310
  1.310
  1.310
Adjusted equity ratio
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432
  0.432

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -53
  -83
  -124
  -181
  -256
  -352
  -473
  -622
  -801
  -1,013
  -1,258
  -1,539
  -1,856
  -2,209
  -2,598
  -3,024
  -3,484
  -3,979
  -4,507
  -5,068
  -5,662
  -6,287
  -6,943
  -7,629
  -8,347
  -9,095
  -9,873
  -10,684
  -11,527
  -12,403
Depreciation, amort., depletion, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  1
  1
  1
  1
  1
  1
  2
  2
  2
  2
  2
  3
  3
  3
  4
  4
  4
  4
  5
Funds from operations, $m
  -53
  -83
  -124
  -181
  -256
  -352
  -473
  -622
  -801
  -1,012
  -1,258
  -1,538
  -1,855
  -2,208
  -2,597
  -3,022
  -3,483
  -3,977
  -4,505
  -5,066
  -5,660
  -6,284
  -6,940
  -7,626
  -8,343
  -9,091
  -9,870
  -10,680
  -11,522
  -12,398
Change in working capital, $m
  -10
  -15
  -21
  -29
  -38
  -49
  -62
  -76
  -91
  -108
  -125
  -143
  -162
  -180
  -198
  -217
  -235
  -252
  -269
  -286
  -302
  -318
  -334
  -350
  -365
  -381
  -397
  -413
  -429
  -446
Cash from operations, $m
  -43
  -67
  -103
  -152
  -217
  -303
  -411
  -546
  -709
  -904
  -1,132
  -1,395
  -1,694
  -2,028
  -2,399
  -2,806
  -3,248
  -3,725
  -4,236
  -4,781
  -5,357
  -5,966
  -6,606
  -7,277
  -7,978
  -8,710
  -9,473
  -10,267
  -11,093
  -11,952
Maintenance CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -4
  -4
  -4
  -4
New CAPEX, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
Cash from investing activities, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -4
  -5
  -5
  -6
  -6
  -6
  -6
Free cash flow, $m
  -43
  -68
  -103
  -152
  -217
  -303
  -412
  -546
  -710
  -905
  -1,133
  -1,396
  -1,695
  -2,030
  -2,401
  -2,808
  -3,250
  -3,727
  -4,239
  -4,783
  -5,361
  -5,970
  -6,610
  -7,281
  -7,983
  -8,715
  -9,478
  -10,273
  -11,099
  -11,958
Issuance/(repayment) of debt, $m
  9
  16
  22
  30
  40
  52
  65
  80
  96
  113
  131
  150
  169
  189
  208
  227
  246
  264
  282
  299
  316
  333
  350
  366
  382
  399
  415
  432
  449
  467
Issuance/(repurchase) of shares, $m
  60
  95
  141
  204
  286
  391
  523
  683
  874
  1,099
  1,358
  1,653
  1,985
  2,352
  2,756
  3,196
  3,671
  4,179
  4,722
  5,296
  5,903
  6,540
  7,209
  7,908
  8,637
  9,398
  10,189
  11,013
  11,868
  12,758
Cash from financing (excl. dividends), $m  
  69
  111
  163
  234
  326
  443
  588
  763
  970
  1,212
  1,489
  1,803
  2,154
  2,541
  2,964
  3,423
  3,917
  4,443
  5,004
  5,595
  6,219
  6,873
  7,559
  8,274
  9,019
  9,797
  10,604
  11,445
  12,317
  13,225
Total cash flow (excl. dividends), $m
  26
  43
  61
  82
  109
  140
  176
  216
  260
  307
  356
  407
  459
  512
  564
  615
  666
  716
  765
  812
  858
  904
  949
  993
  1,037
  1,081
  1,126
  1,172
  1,218
  1,266
Retained Cash Flow (-), $m
  -60
  -95
  -141
  -204
  -286
  -391
  -523
  -683
  -874
  -1,099
  -1,358
  -1,653
  -1,985
  -2,352
  -2,756
  -3,196
  -3,671
  -4,179
  -4,722
  -5,296
  -5,903
  -6,540
  -7,209
  -7,908
  -8,637
  -9,398
  -10,189
  -11,013
  -11,868
  -12,758
Prev. year cash balance distribution, $m
  32
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -2
  -52
  -81
  -122
  -177
  -251
  -347
  -467
  -614
  -792
  -1,002
  -1,246
  -1,526
  -1,841
  -2,193
  -2,581
  -3,004
  -3,463
  -3,957
  -4,484
  -5,044
  -5,636
  -6,260
  -6,915
  -7,600
  -8,316
  -9,063
  -9,841
  -10,650
  -11,491
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -2
  -47
  -70
  -100
  -137
  -182
  -234
  -292
  -353
  -415
  -476
  -532
  -580
  -618
  -644
  -656
  -654
  -638
  -609
  -570
  -522
  -468
  -410
  -352
  -296
  -243
  -195
  -152
  -116
  -87
Current shareholders' claim on cash, %
  64.8
  40.9
  26.1
  16.9
  11.1
  7.3
  4.9
  3.3
  2.2
  1.5
  1.1
  0.7
  0.5
  0.4
  0.3
  0.2
  0.1
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

FINANCIAL RATIOS  of  Stemline Therapeutics (STML)

Valuation Ratios
P/E Ratio -5.8
Price to Sales 218.5
Price to Book 3.8
Price to Tangible Book
Price to Cash Flow -7.3
Price to Free Cash Flow -7.3
Growth Rates
Sales Growth Rate 0%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -45.8%
Ret/ On Assets - 3 Yr. Avg. -44.2%
Return On Total Capital -52.1%
Ret/ On T. Cap. - 3 Yr. Avg. -48.9%
Return On Equity -52.1%
Return On Equity - 3 Yr. Avg. -48.9%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -3800%
EBITDA Margin - 3 Yr. Avg. -2500%
Operating Margin -3900%
Oper. Margin - 3 Yr. Avg. -2533.3%
Pre-Tax Margin -3800%
Pre-Tax Margin - 3 Yr. Avg. -2500%
Net Profit Margin -3800%
Net Profit Margin - 3 Yr. Avg. -2500%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

STML stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the STML stock intrinsic value calculation we used $0.898199 million for the last fiscal year's total revenue generated by Stemline Therapeutics. The default revenue input number comes from 0001 income statement of Stemline Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our STML stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for STML is calculated based on our internal credit rating of Stemline Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Stemline Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of STML stock the variable cost ratio is equal to 3800%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for STML stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Stemline Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Stemline Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the STML stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for STML are equal to 8%.

Life of production assets of 5.4 years is the average useful life of capital assets used in Stemline Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for STML is equal to -1937%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $47.070429 million for Stemline Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 30.21 million for Stemline Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Stemline Therapeutics at the current share price and the inputted number of shares is $0.3 billion.

RELATED COMPANIES Price Int.Val. Rating
KPTI Karyopharm The 11.00 0.54  str.sell
CELG Celgene 69.98 340.31  str.buy
EPZM Epizyme 7.51 0.85  str.sell
SGEN Seattle Geneti 54.39 1.07  str.sell
XNCR Xencor 38.96 4.16  str.sell
SNSS Sunesis Pharma 1.25 0.15  str.sell

COMPANY NEWS

▶ Stemline Therapeutics: 3Q Earnings Snapshot   [Nov-08-18 05:17PM  Associated Press]
▶ Benzinga Pro's 5 Stocks To Watch Today   [Aug-13-18 09:25AM  Benzinga]
▶ Stemline Therapeutics: 2Q Earnings Snapshot   [Aug-09-18 08:18AM  Associated Press]
▶ Biotechnology Firm PPCB, Shows Great Potential   [Jun-19-18 10:00AM  ACCESSWIRE]
▶ Stemline Therapeutics: 1Q Earnings Snapshot   [May-09-18 04:26PM  Associated Press]
▶ Stemline Therapeutics reports 4Q loss   [Mar-16-18 08:05AM  Associated Press]
▶ Top 3 Growth Stocks For The Month   [Jan-30-18 11:02AM  Simply Wall St.]
▶ Best-In-Class Growth Stocks   [Dec-25-17 11:02AM  Simply Wall St.]
▶ Stemline Therapeutics reports 3Q loss   [Nov-09-17 05:14PM  Associated Press]
▶ 3 Biotech Stocks That Soared This Week: Are They Buys?   [Nov-04-17 03:02PM  Motley Fool]
▶ Growth Stocks Investors Love   [12:02PM  Simply Wall St.]
▶ Stemline Therapeutics reports 2Q loss   [Aug-08-17 05:48PM  Associated Press]
▶ Stemline Therapeutics reports 1Q loss   [May-10-17 05:38PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.